市场调查报告书
商品编码
1410823
BRCA检验的全球市场 - 规模,各市场区隔,占有率,法规,偿付,预测(~2033年)BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
本报告提供全球BRCA检验市场相关调查分析,提供各市场区隔的市场规模,市场趋势,竞争情形,COVID-19影响等资讯。
市场模式的主要内容如下列。
已上市的BRCA检验与不断变化的竞争格局
世界,地区,国家层级的市场固有考察
透过掌握包含医疗制度概要的真实整体状况来促进对市场的认识。此外在打入市场部门更提供关于给付原则及法规情势之资讯,使您能够更深入地研究市场动态。
对象企业
BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on BRCA tests market for the year 2020 and beyond. The BRCA Tests includes Sanger sequencing Tests, Multiplex Ligation-dependent Probe Amplification (MLPA) Tests, Other BRCA Tests such as array comparative genomic hybridization (aCGH), and also nucleic acid amplification tests (NAATs) and MassArray. It is difficult to detect early stages of ovarian cancer, however, high-risk women with mutations in BRCA1/2 can be closely monitored, or have preventative surgery, such as bilateral salpingo-oophorectomy. Breast cancer is generally subdivided into different categories, depending on expression levels of cellular receptors for estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor 2 (HER2).
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed BRCA tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: NGeneBio Co Ltd, Agilent Technologies Inc, Illumina Inc, NimaGen BV, Qiagen NV, Takara Holdings Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, MRC-Holland BV, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to-
Not Applicable
Not Applicable
Not Applicable